Skip to main content

Table 5 Factors associated with long-term virologic response

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Factors

Univariate analysis

Multivariate analysis

RR

95% CI

P

RR

95% CI

P

Age (years)

1.007

0.995–1.018

0.262

   

Sex (female/male)

1.009

0.747–1.363

0.952

   

HBeAg-positive (−/+)

3.031

2.209–4.158

<0.001

1.834

1.246–2.698

0.002

Disease status (LC/CHB)

1.577

1.172–2.121

0.003

1.028

0.748–1.411

0.867

MELD (<7/≥7)

0.923

0.676–1.260

0.613

   

INR

1.020

0.469–2.218

0.961

   

Serum ALT (IU/L)

1.000

1.000–1.000

0.890

   

Serum total bilirubin (mg/dL)

1.005

0.918–1.101

0.908

   

Serum albumin (g/dL)

1.077

0.824–1.406

0.588

   

IVR-3 (+/−)

4.851

2.902–8.109

<0.001

3.403

1.977–5.859

<0.001

Serum HBV DNA level

(log10 IU/mL)

0.638

0.569–0.715

<0.001

0.817

0.696–0.958

0.013

Therapy regimens (TDF/ETV)

1.162

0.868–1.555

0.313

   
  1. RR relative risk, 95% CI 95% confidence interval, ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, INR international normalized ratio, IVR-3 initial virologic response at 3 months, LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir